Stryker Corporation
Stryker Announces Q1 2025 Results and Raises Guidance
Summary
Stryker Corporation reported an 11.9% increase in net sales for Q1 2025, reaching $5.9 billion. Organic net sales grew by 10.1%, driven by increased unit volume and higher prices. Despite a 17.6% decrease in reported earnings per share to $1.69, adjusted earnings per share increased by 13.6% to $2.84. The company also raised its full-year 2025 organic net sales growth guidance to 8.5% to 9.5%, anticipating a favorable pricing impact and slightly unfavorable foreign exchange impact. A press release with detailed financial information is attached as Exhibit 99.1.
Profitelligence Alerts
Get alerts for SYK
Be first to know when Stryker Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Stryker Corporation
Stryker Corporation is a prominent player in the medical technology industry, known for its innovative solutions across healthcare sectors such as orthopedics, medical and surgical, and neurotechnology and spine. The company's purpose is to enhance patient care through its wide array of products, including surgical equipment and advanced medical devices. Stryker plays a critical role in the healthcare market by providing essential tools and technologies that assist in improving surgical precision and patient recovery processes. With a continuous focus on research and development, Stryker Corporation remains at the forefront of medical advancements, directly impacting hospitals, surgical centers, and healthcare providers globally. The company's extensive distribution network and partnerships with medical professionals ensure that its technologies contribute to improving health outcomes across diverse geographical regions.
Official SEC Documents
Advertisement